Estudio prospectivo sobre la práctica habitual de profilaxis y tratamiento de la infiltración neuromeníngea en pacientes con linfoma no hodgkiniano en España;Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain

Medicina Clinica

Volumn 131, Issue 12, 2008, Pages 441-446

  Sancho, Juan Manuel ^a   Morgades, Mireia ^a   Alonso, Natalia ^b   Deben, Guillermo ^o   de Sevilla, Alberto Fernández ^c   Vázquez, Lourdes ^d   Nicolás, Concepción ^e   García Vela, José Antonio ^f   Arranz, Reyes ^g   Abella, Eugenia ^h   Canales, Miguel Ángel ⁱ   Miralles, Pilar ^j   Sánchez, Eva ^k   Hermosilla, Mar ^l   Conde, Eulogio ^m   Rueda, Antonio ⁿ   Ribera, Josep Maria ^a  

^a Servicio de Hematologia Clinica ICO Hospital Germans Trias i Pujol Universitat Autonoma de Barcelo   (Germany)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l Servicio de Hematología Hospital Josep Trueta Lleida   (Spain)

^m Servicio de Hematología Hospital Marqués de Valdecilla Santander   (Spain)

ⁿ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^o NONE

more..

Author keywords

Central nervous system involvement; Intrathecal; Lymphoproliferative disorders; Non Hodgkin's lymphoma; Prophylaxis; Treatment

Indexed keywords

CYTARABINE; HYDROCORTISONE; LACTATE DEHYDROGENASE; METHOTREXATE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER RADIOTHERAPY; CANCER REGISTRY; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DIPLOPIA; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LIVER METASTASIS; LONGITUDINAL STUDY; LUNG METASTASIS; LYMPHOBLASTOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; PROPHYLAXIS; PROSPECTIVE STUDY; SEIZURE; SENSORY NEUROPATHY; SPAIN; SYMPTOMATOLOGY; T CELL LYMPHOMA; TUMOR VOLUME; VISUAL IMPAIRMENT; VOMITING; CENTRAL NERVOUS SYSTEM TUMOR;

CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PROSPECTIVE STUDIES; SPAIN;

EID: 63149159215     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13126952     Document Type: Article

References (41)

1. Colocci N., Glantz M., and Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: A review of the literature. Semin Neurol 24 (2004) 395-404
2. Franklin J.L., and Finlay J. Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system. Curr Treat Options Neurol 8 (2006) 335-345
3. Keldsen N., Michalski W., Bentzen S.M., Hansen K.B., and Thorling K. Risk factors for central nervous system involvement in non-Hodgkins lymphoma - a multivariate analysis. Acta Oncol 35 (1996) 703-708
4. Bollen E.L., Brouwer R.E., Hamers S., Hermans J., Kluin M., Sankatsing S.U., et al. Central nervous system relapse in non-Hodgkin lymphoma. Asingle-center study of 532 patients. Arch Neurol 54 (1997) 854-859
5. Van Besien K., Ha C.S., Murphy S., McLaughlin P., Rodríguez A., Amin K., et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91 (1998) 1178-1184
6. Tomita N., Kodama F., Sakai R., Koharasawa H., Hattori M., Taguchi J., et al. Predictive factors for central nervous system involvement in non odgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 38 (2000) 335-343
7. Haioun C., Besson C., Lepage E., Thieblemont C., Simon D., Rose C., et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated andreceiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Ann Oncol 11 (2000) 685-690
8. Hollender A., Kvaloy S., Nome O., Skovlund E., Lote K., and Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 13 (2002) 1099-1107
9. Feugier P., Virion J.M., Tilly H., Haioun C., Marit G., Macro M., et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15 (2004) 129-133
10. Boehme V., Zeynalova S., Kloess M., Loeffler M., Kaiser U., Pfreundschuh M., et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18 (2007) 149-157
11. Björkholm M., Hagberg H., Holte H., Kvaloy S., Teerenhovi L., Anderson H., et al. Central nervoussystem occurrenve in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 18 (2007) 1085-1089
12. McMillan A. Central Nervous system-directed preventive therapy in adults with lymphoma. Br J Haematol 131 (2005) 13-21
13. Hegde U., Filie A., Little R.F., Janik J.E., Grant N., Steinberg S.M., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105 (2005) 496-502
14. Bromberg J.E.C., Breems D.A., Kraan J., Bikker G., Van der Holt B., Sillevis Smitt P., et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 68 (2007) 1674-1679
15. Quijano S., López A., Deben G., Plaza J., Poderós C., Provencio M., et al. Identificación de infiltración neoplásica del LCR en pacientes con LNH-B agresivosin evidencia de enfermedad leptomeníngea: análisis comparativo de la utilidad de la citometría de flujo (CMF) vs citología convencional (CITC). Hae matologica (Ed esp) 91 Extr 2 (2006) 74
16. Chua S.L., Seymour J.F., Streater J., Wolf M.M., Januszewicz E.H., and Prince H.M. Intrathecal chemo therapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 43 (2002) 1783-1788
17. García-Manero G., and Glantz M. Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?. Expert Rev Neurotherapeutics 4 Suppl 1 (2004) S25-S31
18. Cheung C.W., Burton C., Smith P., Linch D.C., Hos-kin P.J., and Ardeshna K.M. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 131 (2005) 193-200
19. Buckstein R., Lim W., Franssen E., and Imrie K.L. CNS prophylaxis and treatment in non-Hodgkin's lymp-homa: variation in practice and lessons from the literature. Leuk Lymphoma 44 (2003) 955-962
20. Sancho JM, Morgades M, Arranz R, FernándezAbellán P, Deben G, Alonso N, et al, on behalf of investigators of QUIT Study (PETHEMA, GELTA-MO and GOTEL Groups). Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc) (En prensa).
21. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia. November 1997. J Clin Oncol 17 (1999) 3835-3849
22. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
23. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
24. Hill Q.A., and Owen R.G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20 (2006) 319-332
25. Oriol A., Ribera J.M., Esteve J., Sanz M.A., Brunet S., Garcia-Boyero R., et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukaemia. Results of the PETHEMA-LAL3/97 study. Haematologica 88 (2003) 445-453
26. Liang R., Chiu E., and Loke S.L. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 8 (1990) 141-145
27. Gholam D., Bibeau F., El Weshi A., Bosq J., and Ribrag V. Primary breast lymphoma. Leuk Lymphoma 44 (2003) 1173-1178
28. Bashir R.M., Bierman P.J., Vose J.M., Weinenburger D.D., and Armitage J.O. Central nervous system involvement in patients with diffuse aggressive non Hodgkin's lymphoma. Am J Clin Oncol 14 (1991) 478-482
29. Chahal S., Lagera J.E., Ryder J., and Kleinschmidt De Masters B.K. Hematological neoplasms with first presentation as spinal cord compression syndromes: a 10-year retrospective series and review of the literature. Clin Neuropathol 22 (2003) 282-290
30. Zucca E., Conconi A., Mughal T.L., Sarris A.H., Seymur J.F., Vitolo U., et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21 (2003) 20-27
31. Fonseca R., Habermann T.M., Colgan J.P., O'Neill B.P., White W.L., Witzig T.E., et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 88 (2000) 154-161
32. NCCN. Non Hodgkin's lymphoma Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, Inc. (citado 1 Oct 2007). Disponible en: http://www.nccn.org
33. Tomita N., Kodama F., Kanamori H., Motomura S., and Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 95 (2002) 576-580
34. Desai J., Mitnick R.J., Henry D.H., Llena J., and Sparano J.A. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin's lymphoma. Cancer 86 (1999) 1840-1847
35. Navarro JT, Vall-Llovera F, Mate JL, Sirera G, Morgades M, Millá F, et al. Decrease in the incidence of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HA-ART. Haematologica. 2007.(En prensa).
36. Kim S., Chatelut C., Kim J.C., Howell S.B., Cates C., Kormanik P.A., et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 11 (1993) 2186-2193
37. Chamberlain M.C., Kormanik P., Howell S.B., and Kim S. Pharmacokinetics of intralumbar DTC 101 for the treatment of leptomeningeal metastases. Arch Neurol 52 (1995) 912-917
38. Glantz M.J., LaFollette S., Jaeckle K.A., Shapiro W., Swinnen L., Rozental J.R., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17 (1999) 3110-3116
39. ®) for intrathecal (i.th.) application in CNS relapse of acute lymphoblastic leukemia (ALL) or very aggressive lymphoma (vaNHL). Gemeinsame Jahrestagung der Detschen, Österreichischen und Schweizerischen Gesellschaften. für Hämatologie und Onkologie. 2005;abstract 789.
40. Mc Clune B., Buadi F.K., Aslam N., and Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphoblastic leukemia and high-grade lymphoma. Leuk Lymphoma 48 (2007) 1849-1851
41. Canales M., Ferreiro J.J., Ferrer S., Salar A., Caballero D., Díaz J.A., et al. Profilaxis del SNC con Depocyte (citarabina liposomal) en pacientes con linfoma difuso de células grandes (LDCG): un análisis preliminar de seguridad en 18 pacientes. Haematologica (Ed esp) 92 Extr 2 (2007) 112